SG Americas Securities LLC reduced its position in shares of Insulet Co. (NASDAQ:PODD) by 74.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,345 shares of the medical instruments supplier’s stock after selling 6,902 shares during the period. SG Americas Securities LLC’s holdings in Insulet were worth $162,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in PODD. Cerebellum GP LLC acquired a new stake in shares of Insulet during the 4th quarter worth approximately $122,000. Diversified Trust Co acquired a new stake in Insulet in the 4th quarter valued at $218,000. Trexquant Investment LP acquired a new stake in Insulet in the 3rd quarter valued at $242,000. Strs Ohio boosted its stake in Insulet by 29.6% in the 3rd quarter. Strs Ohio now owns 7,000 shares of the medical instruments supplier’s stock valued at $385,000 after buying an additional 1,600 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Insulet in the 3rd quarter valued at $406,000.
Shares of Insulet Co. (NASDAQ:PODD) traded down $0.22 during trading on Wednesday, reaching $84.52. The company had a trading volume of 592,707 shares, compared to its average volume of 517,578. Insulet Co. has a twelve month low of $38.43 and a twelve month high of $85.44. The company has a market cap of $4,855.21, a price-to-earnings ratio of -184.13 and a beta of 1.56. The company has a debt-to-equity ratio of 3.57, a current ratio of 6.24 and a quick ratio of 5.85.
Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The firm had revenue of $130.50 million during the quarter, compared to the consensus estimate of $125.16 million. Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The business’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.16) earnings per share. sell-side analysts predict that Insulet Co. will post -0.3 earnings per share for the current fiscal year.
In other news, Director David A. Lemoine sold 641 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $76.81, for a total value of $49,235.21. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Shacey Petrovic sold 1,319 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total value of $101,312.39. The disclosure for this sale can be found here. 2.60% of the stock is owned by insiders.
PODD has been the topic of a number of recent analyst reports. Barclays boosted their price objective on Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research note on Monday, November 20th. BidaskClub downgraded Insulet from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. UBS Group upgraded Insulet from a “market perform” rating to an “outperform” rating in a report on Monday, January 8th. Raymond James Financial raised Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research note on Monday, January 8th. Finally, Zacks Investment Research cut Insulet from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Eight investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $73.24.
ILLEGAL ACTIVITY WARNING: This piece was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/03/14/insulet-co-podd-shares-sold-by-sg-americas-securities-llc.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.